3D Medicines Inc. (HKG:1244)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.63
-0.30 (-3.78%)
Sep 5, 2025, 4:08 PM HKT
-3.78%
Market Cap1.87B
Revenue (ttm)491.34M
Net Income (ttm)-184.64M
Shares Out244.97M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,010,000
Average Volume824,806
Open7.93
Previous Close7.93
Day's Range7.63 - 7.93
52-Week Range1.60 - 8.85
Beta0.41
RSI51.26
Earnings DateAug 25, 2025

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in P... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 191
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1244
Full Company Profile

Financial Performance

In 2024, 3D Medicines's revenue was 445.65 million, a decrease of -29.81% compared to the previous year's 634.95 million. Losses were -182.66 million, -65.19% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.